BioArctic AB

BIOA-B.STPhase 2

Stockholm, SwedenFounded 2003bioarctic.se

BioArctic is a publicly traded Swedish biotech company at the forefront of developing novel treatments for neurodegenerative disorders. Its most significant achievement is the co-development of lecanemab (Leqembi®) with Eisai, which became the first amyloid-targeting therapy to receive traditional FDA approval for Alzheimer's disease. The company leverages its proprietary BrainTransporter® technology to develop antibodies and other biologics that can cross the blood-brain barrier, with a pipeline extending beyond Alzheimer's to Parkinson's disease and other CNS conditions. BioArctic's strategy combines proprietary research with strategic partnerships to advance its clinical programs.

Market Cap

$2.4B

Founded

2003

Employees

50-100

Focus

Biotech

BIOA-B.ST · Stock Price

USD 306.00+204.60 (+201.78%)

Historical price data

AI Company Overview

Technology Platform

Focuses on targeting toxic protein aggregates like amyloid-beta protofibrils and alpha-synuclein. Proprietary BrainTransporter® platform engineers antibodies for enhanced blood-brain barrier penetration via receptor-mediated transcytosis.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
exidavnemab + Placebo Comparator	Parkinson Disease	Phase 2

Funding History

Total raised: $25M

Grant$5MSwedish Research CouncilJun 15, 2019

IPO$20MUndisclosedJun 15, 2017

Opportunities

The primary growth opportunity is the global commercial rollout and lifecycle management of Leqembi, including new formulations (subcutaneous) and potential expansion into pre-symptomatic Alzheimer's.

Successfully advancing its proprietary Parkinson's disease antibody, BAN1202, into the clinic represents a major value-creating milestone.

The BrainTransporter® platform offers further opportunity for new internal candidates or lucrative partnership deals in other CNS indications.

Risk Factors

Key risks include slower-than-expected commercial adoption of Leqembi due to diagnostic, infusion, and safety monitoring challenges.

The clinical development of its proprietary Parkinson's and other pipeline programs carries high risk of failure.

The company also faces intense competition in both the Alzheimer's and Parkinson's disease therapeutic landscapes from large pharmaceutical companies with substantial resources.

Competitive Landscape

In Alzheimer's, BioArctic/Eisai compete directly with Biogen/Eisai's Aduhelm and Eli Lilly's donanemab. In Parkinson's and broader neurodegeneration, competitors include Roche, Biogen, UCB, Prothena, and AC Immune. BioArctic differentiates through its specific focus on toxic protofibrils, validated BBB-penetration technology, and a successful partnership model.

Publications

Patents

Pipeline